Cardiff Oncology, Inc. (CRDF)
0.998
+0.12
(+13.40%)
USD |
NASDAQ |
Aug 24, 16:00
0.9968
0.00 (0.00%)
After-Hours: 20:00
Cardiff Oncology Gross Profit Margin (Quarterly) : -113.5% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -113.5% |
| March 31, 2026 | -439.0% |
| December 31, 2025 | 8.23% |
| September 30, 2025 | -86.67% |
| June 30, 2025 | -89.26% |
| March 31, 2025 | -109.2% |
| December 31, 2024 | 36.42% |
| September 30, 2024 | 38.79% |
| June 30, 2024 | 35.58% |
| March 31, 2024 | 50.24% |
| December 31, 2023 | 33.97% |
| September 30, 2023 | 24.11% |
| June 30, 2023 | 9.26% |
| March 31, 2023 | -8.43% |
| December 31, 2022 | 60.94% |
| September 30, 2022 | 12.90% |
| June 30, 2022 | 58.24% |
| March 31, 2022 | 58.11% |
| December 31, 2021 | -21.80% |
| September 30, 2021 | 0.00% |
| June 30, 2021 | 0.00% |
| March 31, 2021 | 0.00% |
| December 31, 2020 | 0.00% |
| September 30, 2020 | 0.00% |
| June 30, 2020 | 0.00% |
| Date | Value |
|---|---|
| March 31, 2020 | 0.00% |
| December 31, 2019 | 0.00% |
| September 30, 2019 | 0.00% |
| June 30, 2019 | 0.00% |
| March 31, 2019 | |
| December 31, 2018 | -102.2% |
| September 30, 2018 | -177.1% |
| June 30, 2018 | -186.1% |
| March 31, 2018 | -265.9% |
| December 31, 2017 | -107.0% |
| September 30, 2017 | -283.8% |
| June 30, 2017 | -231.6% |
| March 31, 2017 | -548.8% |
| December 31, 2016 | -763.2% |
| September 30, 2016 | -376.4% |
| June 30, 2016 | -296.0% |
| March 31, 2016 | -156.7% |
| December 31, 2015 | -151.9% |
| September 30, 2015 | -202.8% |
| June 30, 2015 | -147.9% |
| March 31, 2015 | -38.98% |
| December 31, 2014 | -43.21% |
| September 30, 2014 | 0.00% |
| June 30, 2014 | 0.00% |
| March 31, 2014 | 0.00% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Ocugen, Inc. | 60.62% |
| CytomX Therapeutics, Inc. | 96.69% |
| ACADIA Pharmaceuticals, Inc. | 90.81% |
| Alnylam Pharmaceuticals, Inc. | 76.88% |
| Anika Therapeutics, Inc. | 65.15% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -93.57% |
| Return on Assets | -69.56% |
| Return on Invested Capital | -91.79% |
| Profit Margin (Quarterly) | -8.88K% |
| Operating Margin (Quarterly) | -9.25K% |
| Return on Net Operating Assets | -2.39K% |